Schizophrenia Research
Volume 88, Issue 1 , Pages 26-35 , December 2006

A longitudinal study of neurocognitive function in individuals at-risk for psychosis

  • Richard S.E. Keefe

      Affiliations

    • Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA
    • Corresponding Author InformationCorresponding author. Box 3270, Duke University Medical Center, Durham, NC 27710, USA. Tel.: +1 919 684 4306; fax: +1 919 684 2632.
    • ,
  • Diana O. Perkins

      Affiliations

    • Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    • ,
  • Hongbin Gu

      Affiliations

    • Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    • ,
  • Robert B. Zipursky

      Affiliations

    • Department of Psychiatry, University of Toronto School of Medicine, Toronto, ON, Canada
    • ,
  • Bruce K. Christensen

      Affiliations

    • Department of Psychiatry, University of Toronto School of Medicine, Toronto, ON, Canada
    • ,
  • Jeffery A. Lieberman

      Affiliations

    • Department of Psychiatry, Columbia University School of Medicine, New York, NY, USA

Received 15 March 2006 ,Revised 27 June 2006 ,Accepted 28 June 2006.

References 

  1. Brewer WJ, Wood SJ, McGorry PD, Francey SM, Phillips LJ, Yung AR, et al. Impairment of olfactory identification ability in individuals at ultra-high risk for psychosis who later develop schizophrenia. Am. J. Psychiatry. 2003;160(10):1790–1794
  2. Brewer WJ, Francey SM, Wood SJ, Jackson HJ, Pantelis C, Phillips LJ, et al. Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. Am. J. Psychiatry. 2005;162(1):71–78
  3. Cannon M, Jones P, Huttunen MO, Tanskanen A, Huttunen T, Rabe-Hesketh S, et al. School performance in Finnish children and later development of schizophrenia: a population-based longitudinal study. Arch. Gen. Psychiatry. 1999;56(5):457–463
  4. Cannon M, Caspi A, Moffitt TE, Harrington H, Taylor A, Murray RM, et al. Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. Arch. Gen. Psychiatry. 2002;59(5):449–456
  5. Cornblatt BA, Keilp JG. Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophr. Bull. 1994;20(1):31–46
  6. Cornblatt B, Obuchowski M, Roberts S, Pollack S, Erlenmeyer-Kimling L. Cognitive and behavioral precursors of schizophrenia. Dev. Psychopathol. 1999;11(3):487–508
  7. Cosway R, Byrne M, Clafferty R, Hodges A, Grant E, Abukmeil SS, et al. Neuropsychological change in young people at high risk for schizophrenia: results from the first two neuropsychological assessments of the Edinburgh High Risk Study. Psychol. Med. 2000;30(5):1111–1121
  8. Fuller R, Nopoulos P, Arndt S, O'Leary D, Ho BC, Andreasen NC. Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance. Am. J. Psychiatry. 2002;159(7):1183–1189
  9. Hambrecht M, Lammertink M, Klosterkotter J, Matuschek E, Pukrop R. Subjective and objective neuropsychological abnormalities in a psychosis prodrome clinic. Br. J. Psychiatry. 2002;43:s30–s37(Suppl.)
  10. Hawkins KA, Addington J, Keefe RS, Christensen B, Perkins DO, Zipursky R, et al. Neuropsychological status of subjects at high risk for a first episode of psychosis. Schizophr. Res. 2004;67(2–3):115–122
  11. Heaton RK, Gladsjo JA, Palmer BW, Kuck J, Marcotte TD, Jeste DV. Stability and course of neuropsychological deficits in schizophrenia. Arch. Gen. Psychiatry. 2001;58(1):24–32
  12. Insel TR. Cure therapeutics and strategic prevention: raising the bar for mental health research. Mol. Psychiatry. 2006;11(1):11–17
  13. Isohanni I, Jarvelin MR, Nieminen P, Jones P, Rantakallio P, Jokelainen J, et al. School performance as a predictor of psychiatric hospitalization in adult life. A 28-year follow-up in the Northern Finland 1966 Birth Cohort. Psychol. Med. 1998;28(4):967–974
  14. Jones P, Rodgers B, Murray R, Marmot M. Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet. 1994;344(8934):1398–1402
  15. Keefe RSE, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am. J. Psychiatry. 2004;161(6):985–995
  16. Keefe RSE, Eesley CE, Poe MP. Defining a cognitive function decrement in schizophrenia. Biol. Psychiatry. 2005;57(6):688–691
  17. Keefe RSE, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, et al. Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biol. Psychiatry. 2006;59(2):97–105
  18. Klosterkotter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch. Gen. Psychiatry. 2001;58(2):158–164
  19. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am. J. Psychiatry. 2003;160(8):1396–4404
  20. Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Cannon T, Ventura J, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr. Bull. 2003;29(4):703–715
  21. Morey RA, Inan S, Mitchell TV, Perkins DO, Lieberman JA, Belger A. Imaging frontostriatal function in ultra-high-risk, early, and chronic schizophrenia during executive processing. Arch. Gen. Psychiatry. 2005;62(3):254–262
  22. Niemi LT, Suvisaari JM, Tuulio-Henriksson A, Lonnqvist JK. Childhood developmental abnormalities in schizophrenia: evidence from high-risk studies. Schizophr. Res. 2003;60(2–3):239–258
  23. Nuechterlein KH, Dawson ME. Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophr. Bull. 1984;10(2):160–203
  24. Phillips LJ, Yung AR, Yuen HP, Pantelis C, McGorry PD. Prediction and prevention of transition to psychosis in young people at incipient risk for schizophrenia. Am. J. Med. Genet. 2002;114(8):929–937
  25. Reichenberg A, Weiser M, Rapp MA, Rabinowitz J, Caspi A, Schmeidler J, et al. Elaboration on premorbid intellectual performance in schizophrenia: premorbid intellectual decline and risk for schizophrenia. Arch. Gen. Psychiatry. 2005;62(12):1297–130
  26. Thompson PM, Vidal C, Giedd JN, Gochman P, Blumenthal J, Nicolson R, et al. Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2001;98(20):11650–11655
  27. Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J, Miller TJ, et al. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol. Psychiatry. 2003;54(4):453–464
  28. Yung Ar, McGorry PD. The initial prodrome in psychosis: descriptive and qualitative aspects. Aust. N. Z. J. Psychiatry. 1996;30(5):587–599
  29. Zammit S, Allebeck P, David AS, Dalman C, Hemmingsson T, Lundberg I, et al. A longitudinal study of premorbid IQ Score and risk of developing schizophrenia, bipolar disorder, severe depression, and other non-affective psychoses. Arch. Gen. Psychiatry. 2004;61(4):354–360

PII: S0920-9964(06)00309-4

doi: 10.1016/j.schres.2006.06.041

Schizophrenia Research
Volume 88, Issue 1 , Pages 26-35 , December 2006

Article Tools

* Image Usage & Resolution